− Clinical Study Evaluating the Use of Duvelisib in Combination with
Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma to be
Highlighted in an Oral Presentation −
− Eight Abstracts Selected in Total, Covering a Wide Variety of
Supportive Clinical and Preclinical Data for Ongoing Development
Programs −
BOSTON--(BUSINESS WIRE)--Nov. 1, 2018--
Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused
on developing and commercializing medicines to improve the survival and
quality of life of cancer patients, today announced that eight abstracts
have been selected for presentation, including one oral presentation, at
the upcoming American Society of Hematology (ASH) 2018 Annual Meeting
being held December 1-4, 2018, in San Diego.
“At ASH this year, we look forward to the presentation of a wealth of
data highlighting further results from the duvelisib development
programs,” said Hagop Youssoufian, MSc, MD, Head of Medical Strategy at
Verastem Oncology. “The breadth of data to be presented at the meeting
reflects our commitment to addressing the clinical needs of patients
with hematologic malignancies by advancing the science behind PI3K-delta
and PI3K-gamma inhibition, underscoring our dedication to develop
practice-changing medicines that improve outcomes for patients.”
Details for the ASH 2018 presentations are as follows:
Oral Presentation
Title: The combination of Duvelisib, a PI3K-δ,γ Inhibitor, and
Romidepsin is highly active in relapsed/refractory peripheral T-cell
lymphoma with low rates of transaminitis: Results of a multicenter,
multi-arm phase 1 study with expansion cohorts
Presenter:
Steven Horwitz, Memorial Sloan Kettering Cancer Center and NYC Health +
Hospitals/Bellevue
Abstract Number/Publication ID: 683
Session:
624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies:
Immunotherapy and Targeted Strategies
Date and Time: Monday,
December 3, 2018; 11:30 AM PT
Location: San Diego Convention
Center, Room 6F
Poster Presentations
Title: Clinical and Biological Indicators of Duvelisib Efficacy
in CLL from the Phase 3 DUO Study
Presenter: Jennifer Brown,
Harvard Medical School and Dana-Farber Cancer Institute
Abstract
Number/Publication ID: 1856
Session: 642. CLL: Therapy,
excluding Transplantation: Poster I
Date and Time: Saturday,
December 1, 2018; 6:15-8:15 PM PT
Location: San Diego
Convention Center, Hall GH
Title: The Efficacy and Safety of Duvelisib Following Disease
Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or
SLL: Updated Results from the DUO Crossover Extension Study
Presenter:
Matthew Davids, Dana-Farber Cancer Institute
Abstract
Number/Publication ID: 3140
Session: 642. CLL: Therapy,
excluding Transplantation: Poster II
Date and Time: Sunday,
December 2, 2018; 6:00-8:00 PM PT
Location: San Diego
Convention Center, Hall GH
Title: Characterization of the Long-Term Efficacy and Safety of
Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on
Treatment for > 2 Years across 4 Clinical Studies
Presenter:
Ian Flinn, Sarah Cannon Research Institute
Abstract
Number/Publication ID: 3146
Session: 642. CLL: Therapy,
excluding Transplantation: Poster II
Date and Time: Sunday,
December 2, 2018; 6:00-8:00 PM PT
Location: San Diego
Convention Center, Hall GH
Title: Simultaneous inhibition of BCL-2 and PI3K signaling
overcomes ibrutinib resistance in mantle cell lymphoma
Presenter:
Haige Ye, MD Anderson Cancer Center
Abstract Number/Publication
ID: 2950
Session: 625. Lymphoma:
Pre-Clinical—Chemotherapy and Biologic Agents: Poster II
Date
and Time: Sunday, December 2, 2018; 6:00-8:00 PM PT
Location:
San Diego Convention Center, Hall GH
Title: Prognostic and Immune-Related Factors for Response to
Duvelisib in the Phase 2 DYNAMO Clinical Trial in iNHL
Presenter:
Pier Luigi Zinzani, University of Bologna Institute of Hematology
Abstract
Number/Publication ID: 4167
Session: 623. Mantle Cell,
Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster
III
Date and Time: Monday, December 3, 2018; 6:00-8:00 PM PT
Location:
San Diego Convention Center, Hall GH
Title: Dual Inhibition of PI3K-δ and PI3K-γ by Duvelisib Impairs
CLL B Cells and CLL-Supporting Cells and Overcomes Ibrutinib Resistance
in a Patient-Derived Xenograft Model
Presenter: Shih-Shih
Chen, The Feinstein Institute for Medical Research, Northwell Health
Abstract
Number/Publication ID: 4420
Session: 642. CLL: Therapy,
excluding Transplantation: Poster III
Date and Time: Monday,
December 3, 2018; 6:00-8:00 PM PT
Location: San Diego
Convention Center, Hall GH
Title: Dynamic BH3 Profiling Predicts Patient Response and MRD
Status in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing
Frontline Treatment with Kinase Inhibitor Augmented (KIA) FCR
Presenter:
Timothy Z. Lehmberg, Dana-Farber Cancer Institute
Abstract
Number/Publication ID: 4395
Session: 641. CLL: Biology
and Pathophysiology, excluding Therapy: Poster III
Date and Time:
Monday, December 3, 2018; 6:00 – 8:00 PM PT
Location: San
Diego Convention Center, Hall GH
About Verastem Oncology
Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical
company committed to the development and commercialization of medicines
to improve the lives of patients diagnosed with cancer. We are driven by
the strength, tenacity and courage of those battling cancer –
single-minded in our resolve to deliver new therapies that not only keep
cancer at bay, but improve the lives of patients diagnosed with cancer.
Because for us, it’s personal.
Our first FDA approved product is now available for the treatment of
patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL).
Our pipeline comprises product candidates that seek to treat cancer by
modulating the local tumor microenvironment. For more information,
please visit www.verastem.com.
Forward Looking Statements Notice
This press release includes forward-looking statements about Verastem
Oncology’s strategy, future plans and prospects, including statements
regarding the development and activity of Verastem Oncology’s lead
product duvelisib, and Verastem Oncology’s PI3K and FAK programs
generally, its intent to commercialize duvelisib, the potential
commercial success of duvelisib, the anticipated adoption of duvelisib
by patients and physicians, the structure of its planned and pending
clinical trials and the timeline and indications for clinical
development, regulatory submissions and commercialization activities.
The words "anticipate," "believe," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "target," "potential," "will,"
"would," "could," "should," "continue," and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include,
among other things, uncertainties regarding the commercial success of
duvelisib in the United States; uncertainties regarding physician and
patient adoption of duvelisib, including those related to the safety and
efficacy of duvelisib; the uncertainties inherent in research and
development of duvelisib, such as negative or unexpected results of
clinical trials; whether and when any applications for duvelisib may be
filed with regulatory authorities in any other jurisdictions; whether
and when regulatory authorities in any other jurisdictions may approve
any such other applications that may be filed for duvelisib, which will
depend on the assessment by such regulatory authorities of the
benefit-risk profile suggested by the totality of the efficacy and
safety information submitted and, if approved, whether duvelisib will be
commercially successful in such jurisdictions; Verastem Oncology’s
ability to obtain, maintain and enforce patent and other intellectual
property protection for duvelisib and its other product candidates; the
scope, timing, and outcome of any legal proceedings; decisions by
regulatory authorities regarding labeling and other matters that could
affect the availability or commercial potential of duvelisib; that
regulatory authorities in the U.S. or other jurisdictions, if approved,
could withdraw approval; whether preclinical testing of Verastem
Oncology’s product candidates and preliminary or interim data from
clinical trials will be predictive of the results or success of ongoing
or later clinical trials; that the timing, scope and rate of
reimbursement for Verastem Oncology’s product candidates is uncertain;
the risk that third party payors (including government agencies) will
not reimburse for duvelisib; that there may be competitive developments
affecting its product candidates; that data may not be available when
expected; that enrollment of clinical trials may take longer than
expected; that duvelisib or Verastem Oncology’s other product candidates
will cause unexpected safety events, experience manufacturing or supply
interruptions or failures, or result in unmanageable safety profiles as
compared to their levels of efficacy; that duvelisib will be ineffective
at treating patients with lymphoid malignancies; that Verastem Oncology
will be unable to successfully initiate or complete the clinical
development and eventual commercialization of its product candidates;
that the development and commercialization of Verastem Oncology’s
product candidates will take longer or cost more than planned; that
Verastem Oncology may not have sufficient cash to fund its contemplated
operations; that Verastem Oncology or Infinity Pharmaceuticals, Inc.
will fail to fully perform under the duvelisib license agreement; that
Verastem Oncology may be unable to make additional draws under its debt
facility or obtain adequate financing in the future through product
licensing, co-promotional arrangements, public or private equity, debt
financing or otherwise; that Verastem Oncology will not pursue or submit
regulatory filings for its product candidates, including for duvelisib
in patients with CLL/SLL or FL in other jurisdictions; and that Verastem
Oncology’s product candidates will not receive regulatory approval,
become commercially successful products, or result in new treatment
options being offered to patients.
Other risks and uncertainties include those identified under the heading
"Risk Factors" in the Company’s Quarterly Report on Form 10-Q for the
quarterly period ended June 30, 2018 as filed with the Securities and
Exchange Commission (SEC) on August 8, 2018, its Annual Report on Form
10-K for the year ended December 31, 2017 as filed with the SEC on March
13, 2018 and in any subsequent filings with the SEC. The forward-looking
statements contained in this press release reflect Verastem Oncology’s
views as of the date hereof, and the Company does not assume and
specifically disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181101005621/en/
Source: Verastem, Inc.
Verastem Oncology:
Brian Sullivan, +1 781-469-1636
Senior
Director, Corporate Development
bsullivan@verastem.com
or
Media:
FleishmanHillard
Adam
Silverstein, +1 917-697-9313
media@verastem.com
or
Investors:
Argot
Partners
Joseph Rayne, +1 617-340-6075
joseph@argotpartners.com